Overview
One of the core functions of Food and Drug Administration (FDA) is to review marketing applications for regulated products to assure their safety, efficacy, and compliance with other regulatory standards. While this is fundamentally a science-based function, the statutory and regulatory rules the FDA must follow have proliferated, public and congressional scrutiny has intensified, and the amount of time, effort, and money required to obtain FDA approval has skyrocketed. Thus, product sponsors frequently encounter situations with the FDA that require legal knowledge and specialized advocacy skills to keep an application on, or return it to, a successful approval pathway. We advise and assist companies in their dealings with the FDA at all stages of product development and FDA review, covering pre-clinical testing, human safety and efficacy studies, development of appropriate application strategies, and the FDA review process itself.
For new drugs, we work closely with clients’ in-house regulatory and scientific personnel and their outside technical consultants to prepare the least burdensome development and approval strategies, and to ensure that the agency’s review of product applications is conducted in conformity with the proper scientific, legal, and regulatory standards.
Contact Us
Ann M. Begley
202.719.4585 | abegley@wiley.law
Related Capabilities
- Digital Health
- Drug Product Development and Approval Strategies
- Enforcement & Recalls
- FDA Regulatory Compliance
- Food and Food Ingredients
- Food & Drug Due Diligence and Transactional Support
- Hatch-Waxman Act Litigation
- Labeling, Advertising, and Promotion
- Litigation and Administrative Advocacy
- Medical Devices
- White Collar Defense & Government Investigations
Related News & Insights
- EventPlan, develop and implement the PV Audit Strategy Plan28th Pharmacovigilance 2022June 16, 2022Jessica L. Vaughn, Ph.D.
- AlertIn Case You Missed It: Takeaways from Final Guidance for Submitting Pre-Launch Activities Importation (PLAIR) Requests to FDA for Drug Products Prior to Anticipated ApprovalMay 23, 2022Amaru J. Sánchez, Jessica L. Vaughn, Ph.D.
- Media MentionDrug Firms Have More Time For First Annual Report On Production Volumes US Is RequiringPharma Intelligence/ InformaFebruary 17, 2022Ann M. Begley
- EventOTC Drug Reform: Moving from Regulations to Orders and What’s NextFood and Drug Law InstituteMay 20, 2021Ann M. Begley